EDITORIAL SECTION

Aclaris Therapeutics Inc NASDAQ ACRS a clinicalstage biopharmaceutical company focused on developing novel product candidates for immunoinflammatory diseases today announced that the US Food and Drug Administration

Galibra Neuroscience announced a significant regulatory milestone with the receipt of both Orphan Drug Designation ODD and Rare Pediatric Disease Designation RPDD from the US Food and Drug Administration

Damora Therapeutics Inc NASDAQ DMRA a biotechnology company working to fundamentally redefine care for patients with blood disorders today announced the initiation of the global Phase b CLARITY clinical trial of DMR

Moderna Inc NASDAQMRNA today announced that the US Food and Drug Administration FDA has approved mFLUSIVA mRNA a new vaccine against seasonal influenza

Greenstone Biosciences has received a Catalyze R grant from the National Heart Lung and Blood Institute NHLBI part of the US National Institutes of Health NIH to support the discovery of new treatments for myocardial fibrosis and dilated cardiomyopathy associated with Duchenne muscular dystrophy DMD

Schrdinger has entered into a strategic collaboration and software agreement with Bristol Myers Squibb BMS to deploy its agentic AI coscientist Bunsen across the companys research organisation to support drug discovery

Takeda has received approval from the US Food and Drug Administration FDA for ORZEYFUL oveporexton making it the first and only treatment approved to address the underlying cause of narcolepsy type NT in adults

Lunai Bioworks has signed a definitive collaboration agreement with BrainStorm Therapeutics to advance the discovery of diseasemodifying therapies for Parkinsons disease The companies are targeting an initial data readout from the collaboration in the first half of

SHY Therapeutics has dosed the first patient in its firstinhuman Phase clinical trial evaluating SHYONC an investigational oral proteasome inhibitor for the treatment of advanced solid tumours The company expects to report initial Phase data in

Taysha Gene Therapies and Catalent have expanded their strategic partnership through a commercial supply agreement for TSHA Tayshas investigational gene therapy for Rett syndrome